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ABSTRACT  
 
The purpose of this project was to develop a new product, purified human hormone 
sensitive lipase (HSL), for Blue Sky Biotech’s product line. This was accomplished by cloning 
the HSL gene by gene synthesis, amplifying the annealed templates by PCR, cloning the 
amplicons into a plasmid in E. coli, packaging the gene into baculovirus, expressing the gene in 
cultured insect cells, and purifying the protein by affinity chromatography using histidine and 
biotin tags contained in the engineered vector. The results indicate that HSL has been purified 
and remains biologically active. Blue Sky Biotech will be able to sell this product to laboratories 
currently researching lipolysis pathways involved in diseases such as obesity, diabetes, and 
hyperlipidemia. 
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 BACK GROUND
HORMONE SENSITIVE LIPASE (HSL)
Hormone sensitive lipase (HSL) is a key enzyme in fatty acid metabolism (Holm et al., 
1988), and it also plays a role in steroidogenesis and overall energy homeostasis. It is an 
intracellular neutral lipase (Kraemer and Shen, 2002) that is capable of hydr
esters, monoacylglycerols, diacylglycerols, and triacylglycerols, 
substrates.  The activity of HSL is regulated both post
and also by pre-translational mechanisms (Kraem
adipose and steroidogenic tissue; however, HSL is also expressed in cardiac muscle, skeletal 
muscle, macrophages, and islets. Its activity can be inhibited by insulin 
catecholamines (via 2-adrenoceptors
catecholamines via ß-adrenoceptors, which promote 
The human hormone sensitive lipase gene (LIPE) is located on chromosome 19, with a 
specific locus of 19q13.1-q13.2 (NCBI, 2008
 
Figure 1: Diagram of the Human
 
 
olyzing cholesterol 
and other water soluble 
-transcriptionally (due to phosphorylation) 
er and Shen, 2002). It is expressed primarily in 
(Large et al., 1998), 
), prostaglandins, and adenosine. HSL can be activated by 
an increase of intracellular cAMP levels.  
).  Figure 1 illustrates the human HSL gene. 
 LIPE Gene. 
 
(NCBI, 2008) 
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 The protein transcribed by the gene has two forms—long and short—which are produced 
through different translational start codons (NCBI, 2008).  Steroidogenic tissues (testes, ovaries, 
adrenals, etc.) express the long form of the protein, which converts cholesterol esters to free 
cholesterol for the production of steroid hormones. Adipose tissue expresses the short form of 
the protein, which hydrolyzes triglycerides to fatty acids (NCBI, 2008).  The short form of the 
protein catalyzes the rate limiting step in adipose tissue lipolysis. The protein exists in the cell 
cytosol, specifically on lipid droplets in adipocytes. The free fatty acids produced during this 
enzymatic reaction are circulated through the bloodstream, and are the primary source of energy 
when a deficiency in dietary substrates exists (Holm et al., 1988). The long form of HSL is 
involved in the hydrolysis of cholesterol esters in the adrenals, ovaries, testes, and macrophages. 
In general, human HSL is activated when energy is needed by the body. Because of this, human 
HSL has a positive response to glucagon and a negative response to insulin. HSL’s 
dephosphorylation can be induced by insulin, which causes the hormone to have an antilipolytic 
effect (Holm at al., 1988).   
Figure 2 shows the contribution of hormone sensitive lipase in lipolysis. Triglycerides 
from the large lipid droplets are hydrolyzed by HSL to free fatty acids and diglyerides. HSL then 
hydrolyzes the diglyerides to free fatty acids and monoglycerides, which are then hydrolyzed to 
free fatty acids and glycerol.  At each hydrolysis the free fatty acids produced become a part of 
the common free fatty acid pool. 
 
 
 
 Figure 2: Diagram of Cellular
 
 
Figure 3 shows the activation and function of HSL within the cell. In mice, CGI
perilipin complexes exist at the cytosolic lipid dro
disrupted for HSL to be eventually phosphorylated. CGI
studied in detail in humans and therefore, the mechanism of action is assumed from the mouse 
model (D'Eustachio, 2005). When the complex dissociates, perilipin is phosphorylated by protein 
kinase A in the presence of ATP.  The phosphorylated perilipin is re
droplet surfaces, and protein kinase A is able to phosphorylate HSL at serine residue 563 in the 
presence of ATP.  Phosphorylated HSL forms a dim
of lipid droplets. From here, it functions to hydrolyze triglycerides to free fatty acid and glycerol, 
and cholesterol esters to cholesterol and free fatty acid
 Lipogenesis versus Lipolysis.  
 
(Albright and Stern, 1998) 
plet surface. These complexes need to be 
-58: perilipin complexes have not been 
-organized on the lipid 
er, and moves from the cytosol to the surface 
 (D'Eustachio, 2005).  
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Figure 3: Diagram of the Activation of HSL. 
 
(D'Eustachio, 2005) 
  Understanding the function of HSL is important in finding a correlation between the 
lipase and several diseases. In order to find this correlation in humans, scientists are interested in 
analyzing the effect of HSL in mice.  
HSL KNOCKOUTS AND TRANSGENIC MICE 
Based on HSL’s known role in lipolysis, researchers have been looking for a direct 
correlation between human hormone sensitive lipase and several diseases, including obesity, 
diabetes, and hyperlipidemia. A recent review, discussed below, from the Department of 
Medicine at Stanford University discussed the effects of HSL knockouts in mice (see below).   
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Figure 4 illustrates the localization of HSL and perilipin in lypolitic stimulation. In basal 
conditions, HSL and fatty acid binding protein (FABP) are localized in the cytosol, while 
perilipin and adipose triglyceride lipase (a droplet associated protein) are localized to the surface 
of lipid droplets within adipocytes. During lipolytic stimulation, protein kinase A is 
phosphorylated, which phosphorylates perilipin and HSL. HSL and FABP are then localized to 
the surface of lipid droplets (Kraemer and Shen, 2002).  
Figure 4: Basal versus Stimulated Localization of HSL and Perilipin.  
 
(Kraemer and Shen, 2002) 
 
In mice where HSL has been inactivated by homologous recombination, physical 
appearance does not seem to be affected (non-obese). However, abnormalities in these KO mice 
are revealed when adipocytes are studied carefully (Kraemer and Shen, 2002). There are 
histological differences in both brown adipose tissue (BAT) and white adipose tissue (WAT).  
BAT has an increase in cell size, and WAT shows an increase in the differences in cell size 
(heterogeneity). Enzyme activity studies show an absence of neutral cholesterol ester hydrolase 
activity in both BAT and WAT, as well as in other tissues where HSL is normally present such 
as adrenal, testes, ovaries, and heart.  Thus, HSL must be solely responsible for all neutral 
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cholesterol ester hydrolase activity. Triacylglycerol lipase activity, on the other hand, was only 
decreased by 40-50% in these mice in WAT, and was similar to wild-type in BAT.  It was 
concluded that triacylglycerol lipases other than HSL must be present in BAT and WAT 
(Kraemer and Shen, 2002).  Researchers have discovered that ATGL (adipose triglyceride lipase) 
accounts for 60-70% of neutral triacylglycerol lipase activity in wild-type and HSL null mice 
(Kraemer and Shen, 2002).  
Interestingly, HSL knockout (KO) mice are resistant to obesity, which makes HSL an 
important drug target. After 15 weeks of high fat diets, HSL null mice were 20-26% lower in 
weight than control mice. Fasting-induced weight loss and body temperatures in HSL KO mice 
were also observed (Kraemer and Shen, 2002). In addition, transcription factors were suppressed 
and mRNA expression of adipose differentiation markers including adiponectin, leptin, resistin, 
and adipsin were significantly decreased (60-90%). With the changes in gene expression because 
of the removal of HSL, lipolysis has been disrupted, and lipogenesis has been severely reduced.  
The alterations in mice resulting from the knockout of hormone sensitive lipase are concluded to 
be the following: lipase and lipid droplet-associated protein expression decreased, the amounts of 
WAT decreased with higher quantities of BAT, macrophages in WAT increased, thermogenesis 
and energy use increased causing resistance to obesity, and adipose differentiation genes 
(transcription factors, fatty acid and triglyceride synthesis enzymes, and alteration of the 
expression of adipocyte differentiation markers) (Kraemer and Shen, 2002).  
The mechanisms for these alterations are not completely understood, but three possible 
mechanisms have been proposed (Figure 5). In part A, diacylglycerol increases in mice without 
HSL since HSL is the major diacylglycerol lipase in adipose tissue. Normal hydrolysis to free 
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fatty acids and glycerol does not occur. Instead, the build-up of diacylglycerol leads to activation 
of the protein kinase C family and targets such as MAPK, which affects cell proliferation, 
apoptosis, and differentiation.  In part B of Figure 5, free cholesterol pools are decreased since 
HSL is the main cholesteryl ester hydrolase in adipose tissue. This leads to a greater amount of 
the transcription factor SREBP2 (sterol regulatory element binding protein 2) and increases in 
transcriptional targets like UCP2 (uncoupling protein 2).  In part C of Figure 5, PPARγ ligands 
that are normally produced as a result of the release of fatty acids by HSL may be lacking in the 
HSL null mice.  This lack of ligands could suppress activation of crucial adipocyte 
differentiation transcription factors, PPARγ and C/EBPα.  
 
Figure 5: Potential Mechanisms of Altered Adipocyte Metabolism in HSL KO Mice. 
 
 
(Kraemer and Shen, 2002) 
 
12 
 
HSL AND MALE STERILITY 
Scientists have also focused on the effect of HSL in the testes.  Research from the 
University of Tokyo and Stanford University was also conducted on HSL knockout mice, 
focusing on both the hydrolysis of cholesterol esters and triacylglycerol.  The HSL gene was 
disrupted by homologous recombination. Figure 6a shows the targeting vector, the wild-type 
HSL allele, and the disrupted allele (Osuga et al., 2000).  Part of exon 5 and all of exon 6, which 
contain the catalytic domain, were deleted from the wild-type allele using the targeting vector to 
form the disrupted allele. The resulting HSL protein is inactive and lacks the C-terminal part.  In 
Figure 6a, the rectangles represent exons, X and E are the restriction enzymes Xbal and EcoRI, 
respectively, and the shaded black box represents the probe used in the Southern blot in Figure 
6b (Osuga et al., 2000).  The Southern blot shows the size differences (5.9 kb wild-type and 2.6 
kb mutated), with the genotypes shown below each lane.  Figure 6c shows immunoblot analysis 
(Western) of WAT (84 kDa) and testes (130 kDa) without immuno-reactive HSL in KO -/- mice 
(Osuga et al., 2000).  
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Figure 6: Homologous Recombination to Produce HSL -/- Mice. 
 
 
 
 
 
 
 
 
 
 
(Osuga et al., 2000) 
HSL -/- male mice were mated with female mice. Vaginal plugs were formed showing 
intercourse was normal, but none of the female mice became pregnant (Osuga et al., 2000).  HSL 
-/- male mice had smaller testes than HSL +/+ male mice, shown by a lower weight: 86 ± 4 
grams vs. 128 ± 6 grams, respectively.  Epididymis preparations were measured for sperm 
counts. HSL -/- male mice had a sperm count of 94 ± 30 spermatazoa per epididymis, and HSL 
+/+ male mice had a sperm count of 7.7 ± 0.4 x 106 spermatazoa per epididymis, which is 
considerably higher for the KO mice, and may indicate a decreased release of sperm in those 
mice (Osuga et al, 2000).  The sperm (60%) in HSL +/+ mice were motile, while none of the 
sperm in HSL -/- mice were motile.  Figure 7 illustrates the difference in the thickness of 
epithelial layers in seminiferous tubules. The thickness was reduced from 12 layers in HSL +/+ 
mice, to 5-7 layers in HSL -/- mice.  There was also a decrease in the number of mature 
spermatids from the HSL +/+ mice to the HSL -/- mice (Osuga et al., 2000).   
14 
 
Figure 7: Analysis of Testes and Epididymus in HSL -/- and HSL +/+ Mice. 
 
 
(Osuga et al., 2000) 
 
 Osuga et al also determined that in HSL -/- mice neutral cholesterol ester hydrolase 
(NCEH) activity was not present in the testes, which contained more cholesterol esters. NCEH 
activities in WAT and BAT were also absent in HSL -/- mice. Although there were phenotypic 
changes, such as enlarged BAT (5-fold) and WAT (2-fold), and BAT mass increase, HSL -/- 
were not obese. Triacylglycerol lipase activities (40% of wild-type) remained in WAT in HSL -/- 
mice.  Thus, Osuga et al determined that HSL is not the only enzyme involved in triacylglycerol 
hydrolysis, and it is necessary for spermatogenesis.  
A study was conducted on testicular HSL and its correlation with male fertility (Kabbaj et 
al., 2001). Testicular HSL was studied because of its importance with male fertility, as described 
in other studies where the KO mice were sterile rather than obese in some cases, proving HSL to 
be an important enzyme in the testis. More significantly, these studies suggest that HSL is 
important in the maintenance of the cholesterol content within the testicular cells. As seen in 
Testes Epididymus 
+/+ 
 -/- 
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Figure 8, there are several forms of HSL with varying molecular weights depending on its 
location: 104, 110, and 120 kDa. The smallest of the molecular weights were found in the 
seminiferous tubules (STf) total homogenate, interstitial tissue (ITf) and the cytosolic and 
lysosomal subcellular fractionations. As the testes developed, expression and activity increased. 
The larger of the molecular weights, 110 and 120 kDa were found only in the lysosomal 
subfraction of the STf homogenate. Although the detection of the testicular HSL in guinea pigs 
showed higher molecular weights than in other tissues, such as adipose tissue, the data does 
match that of studies conducted in other species.  They concluded from their data that part of 
HSL may originate from germ cells, as seen in the HSL activity at varying molecular weights, 
which is then imported into Sertoli cells, which assist in the production of sperm in the male 
reproductive system. During spermatogenesis, spermatids attach to these cells in the 
seminiferous tubules in the testes.   
 
Figure 8: HSL and Male Sterility in Guinea Pigs.  
The figure shows HSL levels in various tissues and subcellular fractions. 
 
(Kabbaj et al., 2001). 
 
Although two isoforms of HSL in rats are currently known, HSLadi and HSLtes (84 kDa 
and 130 kDa respectively) and guinea pigs (104, 110 and 120 kDa) (Lindvall et al., 2003) 
research about HSL in humans, such as its functional importance and expression, must continue 
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(Large et al., 1998). Varying the amount of HSL could greatly impact the capacity in which 
adipose tissue hydrolyzes triacylglycerols.  Increasing HSL mRNA levels two-fold, which was 
associated with plasma free fatty acid levels, was discovered in the adipose tissue of cancer 
patients. A decrease in HSL activity showed a decrease in lipolysis in fat cells of patients with 
combined hyperlipidemia and patients with hereditary obesity (Large et al., 1998).  
HSL ACTIVITY 
Contreras et al. (1998) expressed HSL in SF9 insect cells and purified the protein in two 
steps using anion-exchange chromatography on Q-Sepharose FF and hydrophobic-interaction 
chromatography on phenyl-Sepharose. They then conducted an HSL activity assay based on 
measuring the “[3H] oleic acid released from either tri-[3H]oleoylglycerol (TO), 1(3)-mono-
[3H]oleoyl-2-O-mono-oleoylglycerol (MOME, …), or cholesteryl [3H]oleate (CO)” (Contreras et 
al., 1998).  The HSL activity was measured in a crude extract, and then again after each 
purification step (Table 1).  
Table 1: Human HSL Activity as Measured by Contreras et al. 
 
(Contreras et al., 1998) 
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In a study conducted by Petry et al. (2005), they developed an assay using a 
monoacylglycerol (MAG) containing NBD (NBD-MAG).  This was proven to be an efficient 
substrate for HSL, more specifically, human recombinant and rat adipocyte HSL.  In their study, 
they recorded the kinetics of the reaction between NBD-MAG and HSL over a period of 6 
minutes at OD 481nm (Figure 9A). The 180 µL reaction was incubated at 30°C, and HSL (at a 
concentration of 33 nM) was added after two minutes. Also, they plotted the reaction rate against 
the HSL concentration (in nM) (Figure 9B).   
Figure 9: NDB-MAG Assay for Monitoring HSL Enzymatic Activity  
in Rat Adipocytes and Human Recombinant HSL.  
 
  
(Petry et al., 2005) 
BLUE SKY BIOTECH 
Blue Sky Biotech (Worcester, MA) is a contract research organization in the 
pharmaceutical research and development market, providing both services and products. They 
specialize in gene cloning and expression, protein purification, and assay development. They 
offer services such as gene synthesis; subcloning and plasmid construction; vector construction; 
site-directed mutagenesis; protein expression scouting; scale-up of E. coli, yeast, mammalian and 
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insect cell expression; optimization of expression in bioreactors; and protein, tissue/organ and 
antibody purification. With respect to this project, Blue Sky Biotech is interested in producing 
purified HSL protein to add to their growing product line, which currently consists of 65 
products such as Acetyl CoA Carboxylase (rat liver), human Lymphocyte-specific protein-
tyrosine kinase, autotoxin (human), phosphodiesterases (human), and sirtuin T1 (human), just to 
name a few.  HSL produced by Blue Sky Biotech can be used to facilitate research and drug 
discovery in the fields of obesity, diabetes, and hyperlipidemia. 
19 
 
PROJECT PURPOSE 
The purpose of this project was to clone, express, and purify human hormone sensitive 
lipase (HSL) for Blue Sky Biotech’s product line. Gene synthesis was chosen for the initial 
cloning for convenience and reliability.  Expression in insect cells was chosen due to the high 
levels of expression of exogenous proteins.  Protein purification by two separate epitopes (His 
and biotin tags) was chosen to increase product purity.   
Hormone sensitive lipase affects lipolysis pathways in adipose tissue and the hydrolysis 
of cholesterol esters in steroidogenic tissue, such as the testes. Its activity is inhibited by the 
presence of insulin and activated by the presence of glucagon. Several diseases including 
obesity, diabetes, and hyperlipidemia are involved in varying the levels of HSL. The goal of this 
project is for Blue Sky Biotech to be able to sell this product to laboratories currently researching 
the role of HSL with these diseases.  
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METHODOLOGY 
GENE SYNTHESIS 
Gene synthesis was performed in three segments: P1, P2, and P3 to clone into plasmids 
pDONR-221-P1, pDONR-221-P2, and pDONR-221-P3 (Integrated DNA Technology). A total 
of 100 µL of molecular grade water was added to each of the wells to re-suspend each of the 
oligonucleotides. Once the oligos were entirely re-suspended, 10 µL from each well was then 
mixed together to anneal each of the individual segments. The annealed oligos were then used as 
template in PCR reactions.  Primer mixes to be used in the PCR were made using the same 
primers from the gene synthesis plate; 10 µL of the first primer and 10 µL of the last primer for 
P1, P2, and P3.  Refer to Appendix B for the complete list of primers.  
GENE AMPLIFICATION AND CLONING INTO PFB-HBV3 
GENE AMPLIFICATION AND ASSEMBLY 
PCR was performed for P1, P2, and P3 in a total of 50 µL using primeSTAR HS DNA 
Polymerase from TaKaRa. The PCR products were then gel extracted and purified (Promega’s 
Wizard SV Gel and PCR Clean-Up System). A Gateway (recombination) reaction was 
performed using the PCR product, pDONR vector, TE buffer, and the BP Clonase II enzyme.  
After one hour in 25°C, the three reactions were transformed into E. coli DH5α cells made 
competent by Blue Sky Biotech, and plated on LB+kanamycin plates. A PCR screen was done 
the following day to check for positive clones using a Taq 2X Mater Mix (New England 
BioLabs). The primers used for P1, P2, and P3 were M13R + HSL-P1-750F, M13R + HSL-P2-
740F, and M13R + HSL-P3-735F, respectively. The annealing temperature for PCR was set to 
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52°C for P1, and 55°C for P2 and P3. The positive clones were then miniprepped (Fermentas 
GeneJET Plasmid Miniprep kit) and the samples were sent for sequence validation through 
SeqWright. The sequences were then analyzed using DNADynamo to obtain the positive clone 
numbers to use as the template for PCR assembly. PCR assembly was done in two parts: P1+P2, 
and P2+P3, then assembled into the full size HSL gene.  
CLONING INTO PFB-HBV3 
Once the PCR reactions were completed for P1, P2, and P3, the amplicons were gel 
extracted (Promega), digested using NotI and XhoI (New England BioLabs), and column 
purified (Qiagen QIAquick PCR Purification Kit).  The elution (HSL insert) was then ligated to 
the pFB-HBv3 vector (see Appenix A) and transformed onto LB+ampicillin plates. Once 
positive results were achieved from the colony screens, the samples were miniprepped and 
digested to ensure that they contained the correct insert.  
BACMID PREPARATION 
Once a positive clone was obtained, the DNA was transformed into MAX Efficiency 
DH10 Bac Competent Cells (Invitrogen), which are used in the bac-to-bac baculovirus 
expression system. An expression bacmid with the gene of interest is produced from the 
combination of a donor plasmid, pFastBac, and a parent bacmid containing the lacZa from the 
DH10 bac E. coli strain. The lacZa gene enables blue and white selection of positive 
recombinants (Invitrogen, 2004). The samples were then prepped (Fermentas GeneJET Plasmid 
Miniprep kit), followed by a bacmid PCR.  
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BACULOVIRUS EXPRESSION OF HSL IN INSECT CELLS 
PREPARING P1 VIRUS STOCK 
A viral stock was prepared using SF9 cells diluted to 1.00x106 cells/mL in 36 mL of 
SF900 II SFM media (Invitrogen) supplemented with 10 µg/mL of Gentimicin (Gibco) in a 
125mL flask. A total of 10 µL of bacmid DNA was diluted into 750 µL of Opti-MEM (Gibco) 
media. Separately, 45 µL of Cell Fectin was diluted in 750 µL of Opti-MEM, then combined 
with the bacmid. The resulting 1.5 mL bacmid/cell fectin mixture was incubated at room 
temperature for 30 minutes and then added to 36 mL of SF9 cells. The P1 stock was harvested 
when the viability reached between 60-70%.  
PREPARING SCOUT TEST SAMPLES 
An experiment (SCOUT) was performed to determine the optimal host cell line and 
conditions that yielded the highest levels of HSL expression using the P1 Viral stock and two 
cell lines: SF9 and SF21. Twenty-four hours prior to the scout, the SF9 and SF21 cells were 
seeded using SF900 II SFM media (Invitrogen) and supplemented with 10 µg/mL of Gentamicin 
(Gibco). Cell and viability counts were performed on the Cedex (Innovatis) the following day.  
The P1 viral stock was then used to inoculate six, 50mL flasks containing one of the two cell 
lines and varying dilutions in SF900II SFM media: SF9 1:100, SF9 1:1000, SF9 1:10000, SF21 
1:100, SF21 1:1000, and SF21 1:10000. The viable cell count, total cell count, percent viability, 
and diameter of the cells were recorded over 24-96 hours, after inoculation and samples from 
each of these time points were collected for the Western Blot analysis (amount calculated from 
2.0x106/total cell count). Refer to the SDS-PAGE Analysis and Immunoblotting section for 
sample preparation. Once the most advantageous conditions were found for expression of HSL, a 
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scale-up was performed under these conditions. When the cell viability decreased substantially, 
the 2L culture was harvested and the cell paste was used for the expression and purification of 
HSL.  
CO-EXPRESSION OF HSL AND PBL 
Due to the presence of the biotin acceptor domain on the protein, a co-infection of the 
HSL P1 viral stock and protein biotin ligase (PBL) was performed for further expression and 
purification. Four flasks containing 600mL SF21 cells were grown and split into four further 
flasks for use in the co-infection. Each flask contained 71mL of SF21 cells and 429mL of pre-
warmed SF900 II SFM media (Invitrogen), containing 1ml/L Gentamicin (10 µg/mL) (Gibco) to 
reach a desired density of 7.5x105 cells/mL. Each of the four flasks was infected with 500 µL of 
HSL P1/PBL viruses and mixed with 1 ml of 50 µM biotin. Once the cells grew for 48 hours, 
showing a large increase in diameter, they were harvested. For the harvest, all four flasks were 
combined and mixed into one flask (2L total), and spun at 4,000g for 15 minutes. A total of 
25mL 1XPBS/L was added to each pellet and snap frozen for storage in -80°C.  
PURIFICATION OF HSL 
NACL CONCENTRATION TEST PURIFICATION 
Three small-scale His purifications were performed using Ni-NTA (GE) with varying 
NaCl concentrations in the lysis buffer (20 mM Tris, 5 mM Imidazole, 1.25 mM Brij-35, 1 mM 
Triton X-100, 5 mM Tween 20, and either 150 mM, 300 mM, or 500 mM NaCl, pH 7.5) and 
elution buffer (20 mM Tris, 500 mM Imidazole, 1.25 mM Brij-35, 1 mM Triton X-100, 5 mM 
Tween 20, and either 150 mM, 300 mM, or 500 mM NaCl, pH 7.5).  Half of a gram of cell paste 
from the 2L HSL expression harvest was resuspended in 5 ml of each of the three NaCl 
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concentrations. The resuspended cells were lysed by sonication and each lysate was centrifuged 
(20,000 rpm for 20 minutes) to separate the supernatant (soluble protein) from the pellet 
(insoluble fraction including the cell membrane). The protein in the supernatants was bound to 
washed Ni-NTA (GE) resin overnight at 4˚ with constant agitation. Each sample was poured into 
a column, and beads were washed with the appropriate lysis buffer, washed again with 25 mM 
Imidazole in the appropriate buffer, and eluted with 150 mM, 300 mM, and 500 mM Imidazole 
in 3 fractions each concentration. The fractions were analyzed by SDS-PAGE, Coomassie-
stained and Western blotted, to determine the most effective NaCl concentration for binding.  
NI-NTA PURIFICATION 
 A large scale His purification was performed using cold lysis (20 mM Tris, 5 mM 
Imidazole, 1.25 mM Brij-35, 1 mM Triton X-100, 5 mM Tween 20, and 300 mM NaCl, pH 7.5) 
and cold elution (20 mM Tris, 500 mM Imidazole, 1.25 mM Brij-35, 1 mM Triton X-100, 5 mM 
Tween 20, and 300 mM NaCl, pH 7.5) buffers. A 1L pellet from the HSL/pBL co-expression 
harvest was weighed and resuspended in an appropriate amount of lysis buffer (10 milliliters 
buffer per 1 gram cell paste). A protease inhibitor cocktail was added to the resuspension to 
reduce protein degradation. The resuspended cells were lysed by sonication and the lysate was 
centrifuged (20,000 rpm for 60 minutes at 4˚C). The supernatant was incubated with pre-
equilibrated Ni-NTA (GE) resin overnight at 4˚ with constant agitation. A protease inhibitor 
cocktail was added to the resin and supernatant to reduce protein degradation. The resin and 
supernatant were poured into a column, and the beads were washed with lysis buffer, washed 
again with 25 mM Imidazole, and eluted with 150 mM, 300 mM, and 500 mM Imidazole in 3 
fractions each. The flow through, washes, and fractions, as well as samples from each step before 
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the sample was added to the column, were analyzed by SDS-PAGE, Coomassie-stained and 
Western blotted to determine purity.  
DIALYSIS 
 Protein samples were dialyzed to exchange buffers and eliminate imidazole from the 
samples. The pooled fractions from the His purification were added to 12 kD dialysis tubing 
(FisherBrand) and exchanged into 4L 1X PBS and 10% glycerol at pH 7.4.  
BIOTIN PURIFICATION 
 The dialyzed biotinylated protein from the His purification was loaded onto washed and 
1X PBS equilibrated SoftLink Avidin resin (Promega) in a column at 4˚C. The column was 
washed with 1X PBS and eluted using 5 mM biotin (dissolved in NaOH and diluted 1:20 in 1X 
PBS) into several fractions. The flow through, wash, and fractions were analyzed by SDS-
PAGE, Coomassie-stained and Western blotted to determine purity.  
BRADFORD AND NANODROP PROTEIN CONCENTRATION ESTIMATION ASSAYS 
 The Ni-NTA purified protein concentration was estimated using two different methods, a 
Bradford estimation and a NanoDrop estimation. In the Bradford method, a 1:2 serial dilution of 
Bovine Serum Albumin (BSA) was used as a standard concentration curve in a 95 well plate. A 
serial dilution of His purified protein was performed starting with 5 µl of undiluted protein, and 
diluting 1:2 with water serially. Bradford Reagent (195 µl) was added to each well containing 
either the BSA standard or the HSL protein. The samples were incubated at room temperature for 
5 minutes and then analyzed using SoftMax Pro 5.2 software.  
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 Protein estimation was done using the NanoDrop 1000 (Thermo Scientific) to verify the 
Bradford Assay. The apparatus was blanked with 2 µl of 1X PBS and then 2 µl of HSL protein 
was analyzed using NanoDrop 1000 V3.7.1.   
SDS PAGE ANALYSIS AND IMMUNOBLOTTING 
 Samples from the test purification, His purification, and Biotin purification were prepped 
using 80 µl of SDS-PAGE loading dye and 20 µl of sample, boiled at 95°C for 5 minutes, and 
loaded onto either 7.5% or 4-20% SDS-PAGE gels to be analyzed using Coomassie-staining or 
Western blot analysis. Gels were run for one hour at 160 volts, and either Coomassie-stained or 
Western blotted. Gels for Western blot analysis were transferred to PVDF membranes for one 
hour at 100 volts with constant stirring. The membranes were blocked in milk for 20-30 minutes 
and left in primary antibody overnight. The membranes were put in the secondary antibodies for 
two hours before developing in Western Blue Stabilized Substrate for Alkaline Phosphatase 
(Promega). The antibodies used included mouse anti-His mAb (primary) diluted 1:7,500 
(Clontech) with a secondary of goat anti-mouse IgG-AP pAb diluted 1:10,000 (Jackson 
Immuno), rabbit anti-HSL (primary) diluted 1:1,000 (Cell Signal catalog number: 41075) with a 
secondary of goat anti-rabbit IgG-AP diluted 1:5,000 (Vector Labs catalog number: AP100), and 
Streptavidin-AP Conjugate diluted 1:25000 (Pierce) with no secondary antibody needed. No 
optimizations were attempted to increase the specificity of the HSL antibody, nor were other 
manufacturers’ reagents tested. 
PURITY DETERMINATION  
The purity of HSL was determined using the 2100 Bioanalyzer with the Protein 230 Kit 
(Agilent Technologies). The kit contains a chip and reagents used for the analysis of proteins. 
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The chip has several micro-channels that separate proteins by size during electrophoresis. Gel-
dye mix (12 µl), destaining solution (12 µl), protein samples (6 µl), and the ladder (6 µl) were 
loaded into marked wells on the chip. The chip was then placed into the 2100 Bioanalyzer and 
started immediately.  
HSL ACTIVITY ASSAY 
 The activity of HSL was measured using the QuantiChromTM Lipase Assay Kit (DLPS-
100) for rapid colorimetric determination of lipase activity at 412nm (BioAssay Systems). A 
working solution was prepared using the kit reagents (5 mg Color reagent, 140 µl Assay Buffer, 
and 8 µl BALB Reagent per each well of reaction in a 96-well plate). Calibrator (150 µl) and 1x 
PBS (150 µl) were added to separate wells of the plate as controls. Protein samples from the Ni-
NTA purification and the biotin purification were used undiluted and also diluted 1:10 and 1:100 
for this assay. The undiluted, 1:10 diluted, and 1:100 diluted samples (10 µl each) were loaded 
into separate wells of the plate in triplicate from each purification. Working solution (140 µl) 
was added to each sample well, and the absorbance at 412 nanometers was taken every 30 
seconds for a period of one hour. The activity was analyzed using SoftMax Pro 5.2 software and 
calculated using the following equation:  
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RESULTS 
The following results were obtained from the HSL cloning, expression, and purification. 
The results indicate that HSL was successfully cloned into the pFB-HBv3 expression vector, 
transformed into DH10 bac cells (Invitrogen), transfected and expressed in SF21 insect cells co-
infected with HSL P1 virus stock and protein biotin ligase (PBL), and purified using Ni-NTA 
resin followed by a Softlink avidin resin. It was also found that the purified HSL protein is 
biologically active as determined by an activity assay.  
CLONING OF HSL  
HSL was cloned in three segments: P1, P2, and P3, beginning with gene synthesis 
(synthetic primer annealing) followed by PCR. The first PCR was performed for P1, P2, and P3 
(Figure 10); P3 was unsuccessful in the first PCR, but proved successful when repeated (Figure 
10).   
Figure 10: PCR of P1, P2, and P3 HSL Gene Fragments 
from Annealed Oligo DNA Templates. 
Gels prepared with 1% Agarose (American Bioanalytical) in 1X TAE stained with EtBr. 
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Following gene assembly (first PCR reaction), PCR amplification was performed on P1, 
P2, and P3 (Figure 11a). The PCR products were purified from the gels, and despite attempts to 
assemble these three parts, complete assembly was unsuccessful. Assembly in two parts (Figure 
11b) was then performed to determine where the problem was occurring. P1 was repeated after 
failing to assemble with P2 (Figure 11c). By using M13F as the forward primer and HSL P1 as 
the reverse at an annealing temperature of 55°C, all three HSL gene segments were successfully 
assembled together (Figure 11d).  
 
Figure 11: PCR Assembly of P1, P2, and P3. 
Gels prepared with 1% Agarose (American Bioanalytical) in 1X TAE stained with EtBr. 
 
 
The HSL insert (PCR full assembly) was ligated to the expression vector, pFB-HBv3, 
and transformed into E. coli DH5α cells. The cells were incubated overnight, followed by a 
colony (PCR) screen. One sample (HSL #9—a positive from the colony screen) was 
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miniprepped and digested to ensure it contained the correct insert (Figure 12). This positive 
clone was then used for the transformation into DH10 Bac cells.  
Figure 12: HSL Miniprepped and Digested with NotI and XhoI. 
Gels prepared with 1% Agarose (American Bioanalytical) in 1X TAE stained with EtBr. 
 
 
Several bacmids were prepared and screened by PCR to confirm identity.  Of the bacmid 
samples prepped, one sample was determined to be a positive clone (HSL bacmid #4) (Figure 13, 
lane 4), which was then used to prepare the HSL virus stock used for expression and purification.  
Figure 13: HSL Bacmid Quality Control. 
Gels prepared with 1% Agarose (American Bioanalytical) in 1X TAE stained with EtBr. 
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BACULOVIRUS EXPRESSION OF HSL IN INSECT CELLS 
 
A bacteriophage stock was prepared by combining SF9 insect cells with the bacmid DNA 
containing the HSL gene and cell fectin mix. This HSL P1 stock was harvested when the 
viability was between 60 and 70%.  Figure 14 is an immunoblot for α-His-tagged HSL 
illustrating the expression of the HSL P1 virus stock after harvesting.  The expression was 
strongest at 120 hours, and lane 6 shows that the HSL is soluble.  
Figure 14: Analysis of HSL P1 Expression by Western Blot (α-His). 
The arrow denotes the position of HSL protein. 
 
After the P1 stock was prepared, an experiment (SCOUT) was conducted to determine 
the optimal host cell line and conditions that yielded the highest levels of HSL expression. The 
P1 virus stock was used to inoculate the two cell lines (SF9 and SF21) at three dilutions each.  
The cells were monitored every 24 hours until the viabilities were about 70%, and then the cells 
were harvested.  Figure 15 illustrates Western blots (blotted with α-His) of the SCOUT. Panels a 
and b show the Western blots of the SF 9 and SF 21 insect cell line culture media, respectively, 
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of three dilutions (1:100, 1:1,000, and 1:10,000) at four different times (24 hrs, 48 hrs, 72 hrs, 
and 96 hrs). Panels c and d show the Western blots of the SF 9 and SF 21 whole cell lysates and 
soluble fractions, respectively, of three dilutions (1:100, 1:1,000, and 1:10,000) at two different 
times (24 hrs and 48 hrs). Panels e and f show the Western blots of the SF 9 and SF 21 whole 
cell lysates and soluble fractions, respectively, of three dilutions (1:100, 1:1,000, and 1:10,000) 
of two different times (72 hrs and 96 hrs). The description of the lanes loaded for each pair of 
panels is located to the right of the panels. The arrow in panel f indicates the conditions with the 
best expression of HSL. The SF 21 insect cell line at a dilution of 1:1,000 was used for large 
scale expression of HSL and cells were monitored over a period of 96 hours for viability.  
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Figure 15:  SCOUT Experiment.  Western Blots of HSL Expression  
Conditions in Insect Cells (α-His). 
 
PROTEIN PURIFICATION  
After the large scale (2L) expression of HSL in SF21 insect cells under optimal 
conditions, a test purification was conducted in order to determine the optimal NaCl 
concentration that produces the best His-tagged HSL binding to metal chelating resin and purity. 
Figure 16 illustrates analysis of the HSL test His purification. Panels a, b, and c show the 
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Western blots of the test His purification using lysis and elution buffer containing 150 mM NaCl, 
300 mM NaCl, and 500 mM NaCl, respectively, all blotted with α-HSL. The arrow in panel b 
indicates the best binding of HSL to the Ni-NTA resin, and therefore the best purification of 
HSL. The lysis and elution buffers used in the large scale purification of HSL contained 300 mM 
NaCl.  Because the protein specific antibody was used as the primary antibody, these membranes 
should have shown one band containing pure HSL. Some protein-specific antibodies, however, 
show high levels of cross reactivity. Due to the presence of multiple bands, it appears that HSL is 
very unstable and degrades considerably during purification.  
Figure 16: Analysis of HSL Test His Purification (α-HSL Western Blot). 
 
 Once the buffer containing 300 mM NaCl was chosen, a large scale His purification was 
performed on the co-HSL/PBL expressed insect cell pellets in order to purify HSL. Figure 17 
illustrates analysis of the co-HSL/PBL His purification. Panel a shows the Coomassie-stained 
SDS-PAGE gel. Lanes 7-12 on the Coomassie-stained gel show pure HSL as indicated by the 
black box. However, because lane 6 was pooled with lanes 7-12, the pooled sample shown in 
lane 13 appears to contain degraded HSL, indicated by the black arrow. Panel b shows the SDS-
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PAGE gel Western blotted with α-HSL. Panel c shows the SDS-PAGE gel Western blotted with 
α-His.  
Figure 17: Analysis of co-HSL/PBL His Purification.   
The black box denotes purified HSL fractions. 
 
To further purify HSL, fractions containing HSL for the nickel-affinity purification were 
pooled and applied to SoftLink avidin. The biotinylated HSL binds to the mutant avidin on the 
resin, which increases the purity of the protein. Biotin binds avidin so tightly that mutant avidin 
is used in order to elute the protein. Figure 18 illustrates analysis of the co-HSL/PBL Biotin 
purification. Panel a shows the Coomassie-stained SDS-PAGE gel. Panel b shows the SDS-
PAGE gel, transferred, and Western blotted with α-HSL. Panel c shows a Western blot using α-
His as the primary antibody. The black boxes indicate the fractions (1 and 2) that appeared to be 
the most pure in all three panels. Fraction 2 contains the greatest concentration of pure HSL.  
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Figure 18: Analysis of co-HSL/PBL Biotin Purification. 
The black box denotes the purest HSL fractions. 
 
 
 
After the each purification, the concentration of the purified HSL was determined using 
NanoDrop Protein Estimation.  A small amount (2 µl) of 1X PBS was added to the NanoDrop to 
blank the machine and then 2 µl of purified HSL was added for the concentration to be 
measured. The NanoDrop reported the purified HSL after the Ni-NTA purification to be at a 
concentration of 6.55 mg/ml (Figure 19) and 2.46 mg/ml (Figure 20) after the biotin purification. 
The Bradford protein assay reported purified HSL from the Ni-NTA purification to be at a 
concentration of approximately 8 mg/ml (Figure 21). The final volume after the biotin 
purification step was 6 ml, and therefore the final yield was 14.76 mg.  
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Figure 19: NanoDrop Estimation of Protein Concentration from HSL Purification 1. 
 
 
Figure 20: NanoDrop Estimation of Protein Concentration from HSL Purification 2. 
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Figure 21: Bradford Assay Standard Curve Used to Estimate Protein Concentrations. 
 
HSL ACTIVITY 
The biological activity of the purified HSL was found using the QuantiChrom Lipase 
Assay Kit (DLPS-100) for rapid colorimetric determination of lipase activity at 412nm 
(BioAssay Systems). The purified HSL was determined to be biologically active. Table 2 shows 
the results of the activity assay performed on both the His-purified HSL (Purification 1) and the 
biotin-purified HSL (Purification 2). The protein from each purification step was assayed in 
triplicates under varying dilutions: undiluted, 1:10, and 1:100. These values were read every 30 
seconds for a total of 60 minutes (Figures 22 and 23). As seen in Table 2, and Figures 22 and 23, 
the OD activity of the protein samples increased over time, and the undiluted samples tended to 
have a greater OD change over time than the diluted samples. The activity of HSL was 
calculated from the graphs using the following equation: 
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(BioAssay Systems) 
After concluding the protein to be biologically active, its purity was found using the 2100 
Bioanalyzer (Agilent). After the first step of the purification, the purity of the protein was 19.97% and 
after the second step of purification, it reached 80.83% purity. After the second purification step, HSL 
appears to be more pure with fewer bands than the first purification step (data not shown).  
Figure 22: HSL Activity Assay for HSL Purification 1. 
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Figure 23: HSL Activity Assay for HSL Purification 2. 
 
 
Table 2: Summary of HSL Activity Assay Results. 
Purification 1   
Sample OD at 10 min OD at 20 min Activity (U/L) 
Undiluted 0.392 0.405 17.35 
Diluted 1:10 0.329 0.339 13.34 X 10=133.4 
Diluted 1:100 0.269 0.277 10.67 X 100=1,067 
    
Purification 2   
Sample OD at 10 min OD at 20 min Activity (U/L) 
Undiluted 0.42 0.44 26.68 
Diluted 1:10 0.382 0.392 13.34 X 10=133.4 
Diluted 1:100 0.341 0.35 12.01 X 100=1,201 
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DISCUSSION 
The purpose of this project was to develop a new product, purified human hormone 
sensitive lipase (HSL), for Blue Sky Biotech’s product line. Blue Sky Biotech will be able to sell 
this product to laboratories currently researching lipolysis pathways involved in diseases such as 
obesity, diabetes, and hyperlipidemia. The results indicate that HSL was successfully cloned into 
the pFB-HBv3 expression vector, transformed into DH10 bac cells to create a bacmid, 
transfected and expressed in SF21 insect cells co-infected with HSL P1 virus stock and protein 
biotin ligase (PBL), and enriched using Ni-NTA resin followed by a Softlink avidin resin. It was 
also found that the purified HSL protein is biologically active as determined by a lipase activity 
assay (BioAssay Systems). 
The objective of the initial molecular engineering work was to perform gene synthesis of 
three HSL gene fragments: HSL-P1, HSL-P2, and HSL-P3 and clone each into pDONR-221 
individually. Gene synthesis was performed rather than traditional PCR because it is quicker, 
allows for codon optimization, and easier for storage if needed again. There are, however, cons 
to using gene synthesis: expensive, easy to make mistakes or introduce mutations, time 
consuming to put the list of primers together.  By engineering a synthetic gene, it allows for the 
optimization of the nucleic acid sequence while still retaining the amino acid sequence. This was 
done in three segments due to the large size of the HSL gene, approximately 3.2kb. Thus, 
cloning into three vectors and then assembling them together enabled the full-length gene to be 
cloned into the expression vector, pFB-HBv3, and transformed into DH10 bacmid cells for use in 
the transfection. Gel electrophoresis was performed on the final PCR segments (P1, P2, and P3) 
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and it was shown that P1 and P2 had a band present at 1200 bp (Figure 10); however, P3 showed 
no band present (Figure 10) so a second PCR was repeated for P3 and proved successful (Figure 
10); the only difference was that the primers were taken directly from the gene synthesis plate 
instead of the primer mix made previously.  
When all three segments, P1, P2, and P3 were transformed individually, the colonies 
were screened for positive clones using primers specific to each segment. The results showed all 
negative clones, indicating self-ligation. This means that despite the growth of several colonies, 
none of the colonies contained the insert. Before repeating any of the previous steps, this theory 
was tested by setting the annealing temperature to 52°C instead of 55°C, which proved to be 
successful. The temperature for annealing is important because every primer has a temperature at 
which it will optimally anneal to its substrate. This is due to the hydrogen bonds between the 
complementary base pairs.  Out of the many samples (12 for each) that were sent for sequence 
validation, only one from each was actually a positive clone; there were many mutations present 
in the other sequences, again pointing out a potential negative of synthetic cloning.  
The next step involved the complete PCR assembly of P1, P2, and P3 (Figure 11). This 
should have produced a band at around 4.4kb. When this wasn’t the case, P1 and P2 were run 
together through gel electrophoresis, and then P2 and P3 were run together. It was concluded that 
because the band for P1 and P2 was not the correct size (2-2.5kb), the primers for P1 were 
incorrect. The P1 PCR was repeated and the full gene was assembled via PCR, gel extraction, 
column purification, digestion, ligation to the expression vector (pFB-HBv3), transformation, 
and colony (PCR) screening for positive clones. Although positives were visible in the colony 
screen and DNA was present in the minipreps, the digest indicated that there were no positive 
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clones present. To ensure that this was in fact the case, the primers for the colony screen were 
changed to HSL-P2-740F and pFBacR. The predicted size, as seen in Figure 24 below, should 
now be ~1.3kb (indicated in blue) instead of the original design (indicated in red) that would 
only produce the gene at 500bp due to the location of the primers.  
Figure 24: Primer Change to Produce Larger Size 
 
 
The positive clone (#9) was miniprepped, digested (positive because the insert and vector 
were present on gel image), and then transformed into bacmid cells. The bacmid PCR, used to 
determine the positive sample, showed only one of the four samples to be positive (#4), as 
depicted in Figure 25 below. A bacmid without the plasmid or insert will be a very small size; 
however, when the bacmid, plasmid, and insert are present, the size will be substantially greater, 
as seen in the figure below. This bacmid sample was then used to make the P1 virus stock for use 
in the expression and purification of HSL.  
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Figure 25: Positive Bacmid Detection 
 
After the HSL P1 stock was produced, a SCOUT was performed to determine the best 
conditions to express HSL in insect cells, as was described in the methods. Gel electrophoresis 
was performed on the SCOUT samples.  At the time, it was not clear whether HSL was 
intracellular or secreted, so the control media was also run on SDS-PAGE with the SCOUT 
samples. The gels were transferred onto polyvinylidene difluoride (PVDF) membranes, and 
blotted with α-His. Blue Sky Biotech uses PVDF membranes because they tend to be easier to 
handle and to stain than nitrocellulose (Sigma-Aldrich). Figure 15f shows that the best HSL 
expression was seen in the lane that contains the SF21 insect cell line at 1:1,000 dilution after 96 
hours. Because of this, the SF21 insect cell line at a dilution of 1:1,000 was used in the large 
scale expression in both the transfection of HSL and the co-infection of HSL/PBL. Although the 
expression of HSL was best after 96 hours, during the large scale expression of HSL the cells 
had to be harvested when the viability was between 60-70%, which occurred after 72 hours.  
During the large scale expression of the co-infection of HSL/PBL, the cells were harvested at 48 
hours because the cell diameter was too large (~24 µm).  
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 Following the expression of HSL in SF21 insect cells, a test purification using Ni-NTA 
resin was conducted to determine the conditions that produce the greatest amount and highest 
purity of HSL. Three different buffers containing three different NaCl concentrations (150 mM, 
300 mM, and 500 mM) were used in the test purification. The protein concentration in a 
purification buffer affects the ability of the desired protein to bind to the resin. The buffer with 
the protein concentration producing the greatest amount of HSL in the eluted fractions is the 
most appropriate buffer to use in large scale purification. The Westerns were blotted with the 
protein specific antibody (α-HSL) to determine whether HSL was degrading during purification. 
Figure 16 shows that the buffer containing 300 mM NaCl produced a greater amount of HSL and 
therefore it is the concentration that was used in the large scale Ni-NTA purification. The 
numerous bands in Figure 16 show that HSL is very unstable at room temperature and degraded 
considerably during purification. Because this purification was performed at room temperature, it 
was determined that the large scale purification would be conducted at 4˚C with more protease 
inhibitor cocktail added to the cell lysate.  
 The large scale Ni-NTA purification of co-HSL/PBL was performed as described in the 
methods with the buffer containing 300 mM NaCl at 4˚C with more protease inhibitor cocktail. 
Gel electrophoresis was performed on the fractions from the large scale purification. One of the 
gels was stained with Coomassie blue dye, and two gels were transferred onto PVDF 
membranes, and blotted with α-HSL and α-His. The Coomassie-stained gel in Figure 17 shows 
that fractions 4 through 9 were fairly pure (130 kDa HSL band), with a few other faint bands. 
These bands are consistent with bands that are present in the α-HSL Western blot in Figure 17, 
which means that HSL degraded slightly during the large scale Ni-NTA purification. Because 
HSL is unstable, the fractions to pool were determined by a colorimetric test using Bradford 
46 
 
reagent. The fractions that contained the most protein (darkest blue) were pooled and frozen in 
liquid nitrogen to prevent further degradation; fractions 3 through 9 were pooled. As seen in the 
Coomassie stained gel in Figure17a, fraction 3 was impure and contained degraded HSL. 
Because this fraction was pooled with the pure fractions (4-9), the pooled fractions sample in 
lane 13 was impure. As a result, the large scale Ni-NTA purification was not successful in 
producing pure HSL and purification using SoftLink avidin resin was necessary.  
 The pooled fractions from the large scale Ni-NTA purification were applied to SoftLink 
avidin resin, washed, and bound protein was eluted with 5 mM biotin. Gel electrophoresis was 
performed on the fractions from this purification. One of the gels was stained with Coomassie 
blue dye and two gels were transferred onto PVDF membranes and blotted with α-HSL and α-
His. Biotin binds tightly to avidin and the resin contains mutant avidin; biotinylated proteins can 
bind to the resin, but not so tightly that they cannot be eluted off. The biotinylated HSL in the 
applied sample adhered to the mutant avidin; however, HSL and other proteins that are not 
biotinylated flowed through the column. Lane 3 in Figure 18a is the flow through from the biotin 
purification, which shows a dark band at the 130 kDa molecular weight marker. This band 
represents HSL that was not biotinylated during expression. A considerable amount of HSL was 
lost due to this and could be prevented by adding more biotin to the co-infection to increase the 
biotinylation of HSL. Ten fractions were collected during the elution, but fractions 5 through 10 
did not contain protein. In fractions 1 and 2, the undiluted elution buffer (100 mM biotin 
dissolved in 100 mM NaOH) was used accidentally. This mistake was corrected in fractions 3 
through 10 by using the diluted elution buffer (100 mM biotin dissolved in 100 mM NaOH and 
diluted 1:20 in 1X PBS to produce 5 mM biotin). However, the undiluted buffer caused complete 
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elution of the protein in fractions 1 through 4 as seen in Figure 18. Fractions 1 and 2 appear to 
contain a considerable amount of pure HSL at the 130 kDa molecular weight marker.   
An activity assay was performed on samples of HSL after each purification step. The 
absorbance measurements of undiluted, diluted 1:10, and diluted 1:100 purified HSL are shown 
in Figures 22 and 23. Contreras et al. (1998) measured HSL activity to be around 11,670 mU/ml 
after their final purification step. As seen in Table 2, the undiluted HSL after the last purification 
step was only about 26.7 U/L and appears to increase as the dilution factor increases. It is 
possible that the working solution from the activity assay did not contain enough substrate for 
the amount of HSL in the undiluted and somewhat diluted samples in order to determine an 
accurate measurement of the enzymatic activity of HSL. It is possible that all of the substrate in 
the working solution was already bound to enzyme before 10 minutes and only bound complex 
and unbound enzyme were left in the reaction wells. As a result, the change in optical density 
(OD) between 10 and 20 minutes was very small. Because the equation to determine the activity 
of the protein uses the change in ODs between 10 and 20 minutes, the activity calculations may 
not be accurate. If the samples had been diluted 1:1,000, the reaction would be slower since the 
enzyme and substrate would collide less frequently and a lower concentration of enzyme may 
allow for complete complex formation. It is possible that our activity measurement at a dilution 
of 1:1,000 would support that of Contreras et al. (1998). As the data currently is, however, it is 
difficult to report how active our purified HSL is.  
 The purity of HSL increased after the first purification step, reaching a total purity of 
80.83%. After the first purification step, the purity was at 19.97%. By analyzing the graph (data 
not shown) of the data, it is evident that the protein became purer as seen by the number of other 
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bands on the gel. Though it appears that the concentration of HSL decreased slightly, the purity 
increased relative to the first purification step.  
In the future, we recommend that Blue Sky Biotech add more biotin to the co-infection in 
order to produce more biotinylated HSL to increase the yield of product, and that they dilute our 
purified HSL 1:1,000 and 1:10,000 to determine a more accurate activity measurement. After an 
accurate activity measurement has been determined, Blue Sky Biotech will be able to produce 
purified HSL using our methodology. This purified HSL can be sold in order to further research 
into diseases such as obesity, diabetes, and hyperlipidemia. 
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A P P E N D I X  A  
The following figure shows the expression vector, pFB-HBv3 used for the design of HSL.  
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A P P E N D I X  B   
The following are the protein sequences and list of primers used for P1 gene synthesis. 
Protein sequence for synthesis:  The red amino acids denote the signal sequence. 
ENLYFQGEPGSKSVSRSDWQPEPHQRPITPLEPGPEKTPIAQPESKTLQGSNTQQKPASNQRPLTQQETPA
QHDAESQKEPRAQQKSASQEEFLAPQKPAPQQSPYIQRVLLTQQEAASQQGPGLGKESITQQEPALRQRHV
AQPGPGPGEPPPAQQEAESTPAAQAKPGAKREPSAPTESTSQETPEQSDKQTTPVQGAKSKQGSLTELGFL
TKLQELSIQRSALEWKALSEWVTDSESESDVGSSSDTDSPATMGGMVAQGVKLGFKGKSGYKVMSGYSGTS
PHEKTSARNHRHYQDTASRLIHNMDLRTMTQSLVTLAEDNIAFFSSQGPGETAQRLSGVFAGVREQALGLE
PALGRLLGVAHL 
 
DNA sequence after addition of GATEWAY recombination sequences: 
Gateway 5’ end 
GGGGACAAGTTTGTACAAAAAAGCAGGCT 
Gateway 3’ end 
ACCCAGCTTTCTTGTACAAAGTGGTCCCC 
 
1 GGGGACAAGTTTGTACAAAAAAGCAGGCTGCGGCCGCTGAGAATCTGTACTTTCAGGGAG 
  61 AGCCCGGCTCCAAGTCCGTCTCGCGCTCGGATTGGCAACCAGAACCACACCAGCGTCCCA 
 121 TCACCCCGTTGGAACCCGGCCCAGAGAAAACGCCGATCGCTCAGCCGGAATCCAAAACCT 
 181 TGCAGGGCTCGAACACGCAGCAGAAACCAGCTTCGAATCAACGCCCGCTGACCCAGCAGG 
 241 AGACGCCAGCCCAGCACGACGCTGAAAGCCAAAAGGAACCGCGTGCCCAACAGAAATCCG 
 301 CTTCGCAAGAGGAATTTCTGGCTCCCCAGAAGCCAGCTCCGCAACAATCGCCATATATCC 
 361 AGCGCGTGTTGCTGACGCAGCAAGAAGCCGCCTCGCAGCAAGGACCAGGATTGGGCAAGG 
 421 AGTCCATTACGCAACAGGAGCCCGCTTTGCGCCAGCGCCACGTCGCTCAACCAGGTCCCG 
 481 GACCGGGCGAGCCACCGCCAGCTCAACAAGAGGCTGAGTCGACCCCCGCTGCTCAGGCTA 
 541 AACCAGGCGCTAAGCGTGAACCATCCGCCCCAACCGAGTCCACCTCCCAGGAAACCCCAG 
 601 AGCAGTCCGATAAACAAACGACGCCGGTCCAAGGAGCTAAGTCCAAACAGGGTAGCTTGA 
 661 CGGAACTGGGTTTTCTGACCAAACTGCAAGAACTGTCCATCCAACGCTCCGCCTTGGAAT 
 721 GGAAGGCCCTGTCGGAGTGGGTCACCGATAGCGAGAGCGAATCGGATGTCGGAAGCTCGT 
 781 CCGACACCGACTCGCCGGCTACGATGGGAGGAATGGTCGCCCAGGGAGTCAAACTGGGAT 
 841 TTAAGGGCAAGAGCGGTTACAAGGTCATGTCGGGCTATTCGGGCACGTCCCCGCATGAAA 
 901 AAACCTCGGCCCGTAATCACCGTCACTATCAAGACACGGCCTCGCGTCTGATCCACAACA 
 961 TGGATTTGCGTACCATGACGCAATCGTTGGTGACGTTGGCCGAAGATAACATCGCCTTTT 
1021 TTTCCAGCCAGGGACCCGGTGAAACCGCCCAACGTTTGAGCGGAGTCTTTGCTGGAGTCC 
1081 GTGAACAAGCCTTGGGTCTGGAACCGGCTTTGGGTCGCTTGTTGGGAGTGGCCCATCTGT 
1141 AGACCCAGCTTTCTTGTACAAAGTGGTCCCC 
 
Gene synthesis:  
 
1 GGGGACAAGTTTGTACAAAAAAGCAGGCTGCGGCCGCT  38 
  2 CGGGCTCTCCCTGAAAGTACAGATTCTCAGCGGCCGCAGC  40 
  3 CTTTCAGGGAGAGCCCGGCTCCAAGTCCGTCTCGCGCTCG  40 
  4 CGCTGGTGTGGTTCTGGTTGCCAATCCGAGCGCGAGACGG  40 
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  5 CCAGAACCACACCAGCGTCCCATCACCCCGTTGGAACCCG  40 
  6 TGAGCGATCGGCGTTTTCTCTGGGCCGGGTTCCAACGGGG  40 
  7 AAAACGCCGATCGCTCAGCCGGAATCCAAAACCTTGCAGG  40 
  8 TTTCTGCTGCGTGTTCGAGCCCTGCAAGGTTTTGGATTCC  40 
  9 TCGAACACGCAGCAGAAACCAGCTTCGAATCAACGCCCGC  40 
 10 GGGCTGGCGTCTCCTGCTGGGTCAGCGGGCGTTGATTCGA  40 
 11 GGAGACGCCAGCCCAGCACGACGCTGAAAGCCAAAAGGAA  40 
 12 GGATTTCTGTTGGGCACGCGGTTCCTTTTGGCTTTCAGCG  40 
 13 CGTGCCCAACAGAAATCCGCTTCGCAAGAGGAATTTCTGG  40 
 14 GGAGCTGGCTTCTGGGGAGCCAGAAATTCCTCTTGCGAAG  40 
 15 CCCAGAAGCCAGCTCCGCAACAATCGCCATATATCCAGCG  40 
 16 CTTGCTGCGTCAGCAACACGCGCTGGATATATGGCGATTG  40 
 17 GTTGCTGACGCAGCAAGAAGCCGCCTCGCAGCAAGGACCA  40 
 18 CGTAATGGACTCCTTGCCCAATCCTGGTCCTTGCTGCGAG  40 
 19 GGGCAAGGAGTCCATTACGCAACAGGAGCCCGCTTTGCGC  40 
 20 GGGACCTGGTTGAGCGACGTGGCGCTGGCGCAAAGCGGGC  40 
 21 CGCTCAACCAGGTCCCGGACCGGGCGAGCCACCGCCAGCT  40 
 22 AGCGGGGGTCGACTCAGCCTCTTGTTGAGCTGGCGGTGGC  40 
 23 AGTCGACCCCCGCTGCTCAGGCTAAACCAGGCGCTAAGCG  40 
 24 GGACTCGGTTGGGGCGGATGGTTCACGCTTAGCGCCTGGT  40 
 25 GCCCCAACCGAGTCCACCTCCCAGGAAACCCCAGAGCAGT  40 
 26 GACCGGCGTCGTTTGTTTATCGGACTGCTCTGGGGTTTCC  40 
 27 ACAAACGACGCCGGTCCAAGGAGCTAAGTCCAAACAGGGT  40 
 28 AAACCCAGTTCCGTCAAGCTACCCTGTTTGGACTTAGCTC  40 
 29 GCTTGACGGAACTGGGTTTTCTGACCAAACTGCAAGAACT  40 
 30 GGCGGAGCGTTGGATGGACAGTTCTTGCAGTTTGGTCAGA  40 
 31 ATCCAACGCTCCGCCTTGGAATGGAAGGCCCTGTCGGAGT  40 
 32 ATTCGCTCTCGCTATCGGTGACCCACTCCGACAGGGCCTT  40 
 33 CCGATAGCGAGAGCGAATCGGATGTCGGAAGCTCGTCCGA  40 
 34 CCCATCGTAGCCGGCGAGTCGGTGTCGGACGAGCTTCCGA  40 
 35 GCCGGCTACGATGGGAGGAATGGTCGCCCAGGGAGTCAAA  40 
 36 CCGCTCTTGCCCTTAAATCCCAGTTTGACTCCCTGGGCGA  40 
 37 GATTTAAGGGCAAGAGCGGTTACAAGGTCATGTCGGGCTA  40 
 38 TTCATGCGGGGACGTGCCCGAATAGCCCGACATGACCTTG  40 
 39 CACGTCCCCGCATGAAAAAACCTCGGCCCGTAATCACCGT  40 
 40 ACGCGAGGCCGTGTCTTGATAGTGACGGTGATTACGGGCC  40 
 41 CACGGCCTCGCGTCTGATCCACAACATGGATTTGCGTACC  40 
 42 TCACCAACGATTGCGTCATGGTACGCAAATCCATGTTGTG  40 
 43 TGACGCAATCGTTGGTGACGTTGGCCGAAGATAACATCGC  40 
 44 GGTCCCTGGCTGGAAAAAAAGGCGATGTTATCTTCGGCCA  40 
 45 TTTTCCAGCCAGGGACCCGGTGAAACCGCCCAACGTTTGA  40 
 46 ACGGACTCCAGCAAAGACTCCGCTCAAACGTTGGGCGGTT  40 
 47 GTCTTTGCTGGAGTCCGTGAACAAGCCTTGGGTCTGGAAC  40 
 48 TCCCAACAAGCGACCCAAAGCCGGTTCCAGACCCAAGGCT  40 
 49 GGGTCGCTTGTTGGGAGTGGCCCATCTGTAGACCCAGCTT  40 
 50 GGGGACCACTTTGTACAAGAAAGCTGGGTCTACAGATGG  39 
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The following are the protein sequences and list of primers used for P2 gene synthesis. 
 
Protein sequence for synthesis:  
 
FDLDPETPANGYRSLVHTARCCLAHLLHKSRYVASNRRSIFFRTSHNLAELEAYLAALTQLRALVYYAQRLL
VTNRPGVLFFEGDEGLTADFLREYVTLHKGCFYGRCLGFQFTPAIRPFLQTISIGLVSFGEHYKRNETGLSVA
ASSLFTSGRFAIDPELRGAEFERITQNLDVHFWKAFWNITEMEVLSSLANMASATVRVSRLLSLPPEAFEMP
LTADPTLTVTISPPLAHTGPGPVLVRLISYDLREGQDSEELSSLIKSNGQRSLELWPRPQQAPRSRSLIVHFHG
GGFVAQTSRSHEPYLKSWAQELGAPIISIDYSLAPEAPFPRALEECFFAYCWAIKHCALLGSTGERICLAG 
 
DNA sequence after addition of GATEWAY recombination sequences: 
Gateway 5’ end 
GGGGACAAGTTTGTACAAAAAAGCAGGCT 
Gateway 3’ end 
ACCCAGCTTTCTTGTACAAAGTGGTCCCC 
 
1 GGGGACAAGTTTGTACAAAAAAGCAGGCTATGTTCGACCTGGACCCGGAGACGCCCGCTA 
61 ATGGATACCGTTCCCTGGTGCATACGGCCCGTTGTTGTCTGGCTCACCTGCTGCACAAAA 
  121 GCCGTTACGTCGCTTCGAATCGCCGTTCGATTTTCTTCCGCACCAGCCACAATCTGGCCG 
  181 AGTTGGAAGCCTACTTGGCTGCCTTGACGCAGTTGCGCGCCTTGGTCTACTACGCCCAAC 
  241 GCCTGCTGGTCACGAACCGTCCGGGAGTCTTGTTCTTTGAAGGCGATGAAGGATTGACCG 
  301 CTGATTTTTTGCGTGAGTACGTCACGCTGCATAAGGGCTGCTTCTATGGACGTTGCTTGG 
  361 GCTTTCAATTCACGCCAGCCATCCGTCCCTTTCTGCAAACCATCAGCATCGGATTGGTCT 
  421 CCTTCGGTGAGCACTACAAGCGCAATGAGACCGGTTTGTCCGTCGCCGCTTCCTCGTTGT 
  481 TCACCAGCGGCCGTTTTGCCATTGACCCAGAGTTGCGTGGCGCTGAATTTGAGCGCATTA 
  541 CCCAGAATTTGGACGTGCACTTTTGGAAGGCTTTCTGGAACATCACGGAGATGGAGGTGC 
  601 TGTCGTCGCTGGCTAACATGGCTTCGGCTACGGTCCGCGTGAGCCGTCTGTTGTCCCTGC 
  661 CACCCGAGGCCTTTGAGATGCCGCTGACGGCTGATCCCACGCTGACCGTCACGATCTCGC 
  721 CACCGTTGGCTCATACCGGACCAGGACCCGTCTTGGTCCGTTTGATTAGCTATGACCTGC 
  781 GCGAGGGTCAAGACAGCGAAGAATTGTCCAGCTTGATTAAGAGCAATGGCCAGCGTAGCC 
  841 TGGAGTTGTGGCCGCGTCCACAGCAAGCTCCGCGTTCCCGCTCCCTGATCGTCCACTTTC 
901 ATGGTGGAGGATTTGTCGCCCAGACGTCGCGCTCGCATGAACCCTATTTGAAGAGCTGGG 
  961 CTCAGGAGTTGGGAGCCCCGATCATCTCGATTGATTACTCCTTGGCTCCGGAAGCTCCAT 
1021 TCCCGCGTGCTTTGGAGGAATGCTTCTTTGCTTATTGCTGGGCCATCAAGCACTGCGCCC 
1081 TGTTGGGATCGACGGGTGAACGCATTTGTTTGGCCGGATAGACCCAGCTTTCTTGTACAA 
1141 AGTGGTCCCC 
 
Gene synthesis:  
 
1 GGGGACAAGTTTGTACAAAAAAGCAGGCTATGTTCGA  37 
  2 GCGTCTCCGGGTCCAGGTCGAACATAGCCTGCTTTTTTGT  40 
  3 TGGACCCGGAGACGCCCGCTAATGGATACCGTTCCCTGGT  40 
  4 ACAACAACGGGCCGTATGCACCAGGGAACGGTATCCATTA  40 
  5 CATACGGCCCGTTGTTGTCTGGCTCACCTGCTGCACAAAA  40 
  6 GATTCGAAGCGACGTAACGGCTTTTGTGCAGCAGGTGAGC  40 
  7 CCGTTACGTCGCTTCGAATCGCCGTTCGATTTTCTTCCGC  40 
  8 CTCGGCCAGATTGTGGCTGGTGCGGAAGAAAATCGAACGG  40 
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  9 GCCACAATCTGGCCGAGTTGGAAGCCTACTTGGCTGCCTT  40 
 10 GACCAAGGCGCGCAACTGCGTCAAGGCAGCCAAGTAGGCT  40 
 11 TTGCGCGCCTTGGTCTACTACGCCCAACGCCTGCTGGTCA  40 
 12 AGAACAAGACTCCCGGACGGTTCGTGACCAGCAGGCGTTG  40 
 13 CGTCCGGGAGTCTTGTTCTTTGAAGGCGATGAAGGATTGA  40 
 14 TCACGCAAAAAATCAGCGGTCAATCCTTCATCGCCTTCAA  40 
 15 CCGCTGATTTTTTGCGTGAGTACGTCACGCTGCATAAGGG  40 
 16 CAAGCAACGTCCATAGAAGCAGCCCTTATGCAGCGTGACG  40 
 17 TGCTTCTATGGACGTTGCTTGGGCTTTCAATTCACGCCAG  40 
 18 TTTGCAGAAAGGGACGGATGGCTGGCGTGAATTGAAAGCC  40 
 19 CATCCGTCCCTTTCTGCAAACCATCAGCATCGGATTGGTC  40 
 20 TTGTAGTGCTCACCGAAGGAGACCAATCCGATGCTGATGG  40 
 21 TCCTTCGGTGAGCACTACAAGCGCAATGAGACCGGTTTGT  40 
 22 ACAACGAGGAAGCGGCGACGGACAAACCGGTCTCATTGCG  40 
 23 GCCGCTTCCTCGTTGTTCACCAGCGGCCGTTTTGCCATTG  40 
 24 TTCAGCGCCACGCAACTCTGGGTCAATGGCAAAACGGCCG  40 
 25 TTGCGTGGCGCTGAATTTGAGCGCATTACCCAGAATTTGG  40 
 26 GCCTTCCAAAAGTGCACGTCCAAATTCTGGGTAATGCGCT  40 
 27 CGTGCACTTTTGGAAGGCTTTCTGGAACATCACGGAGATG  40 
 28 CCAGCGACGACAGCACCTCCATCTCCGTGATGTTCCAGAA  40 
 29 GTGCTGTCGTCGCTGGCTAACATGGCTTCGGCTACGGTCC  40 
 30 GCAGGGACAACAGACGGCTCACGCGGACCGTAGCCGAAGC  40 
 31 CCGTCTGTTGTCCCTGCCACCCGAGGCCTTTGAGATGCCG  40 
 32 GTCAGCGTGGGATCAGCCGTCAGCGGCATCTCAAAGGCCT  40 
 33 GCTGATCCCACGCTGACCGTCACGATCTCGCCACCGTTGG  40 
 34 GACGGGTCCTGGTCCGGTATGAGCCAACGGTGGCGAGATC  40 
 35 CGGACCAGGACCCGTCTTGGTCCGTTTGATTAGCTATGAC  40 
 36 CTTGACCCTCGCGCAGGTCATAGCTAATCAAACGGACCAA  40 
 37 CTGCGCGAGGGTCAAGACAGCGAAGAATTGTCCAGCTTGA  40 
 38 CGCTGGCCATTGCTCTTAATCAAGCTGGACAATTCTTCGC  40 
 39 AAGAGCAATGGCCAGCGTAGCCTGGAGTTGTGGCCGCGTC  40 
 40 AGCGGGAACGCGGAGCTTGCTGTGGACGCGGCCACAACTC  40 
 41 TCCGCGTTCCCGCTCCCTGATCGTCCACTTTCATGGTGGA  40 
 42 ACGTCTGGGCGACAAATCCTCCACCATGAAAGTGGACGAT  40 
 43 GATTTGTCGCCCAGACGTCGCGCTCGCATGAACCCTATTT  40 
 44 ACTCCTGAGCCCAGCTCTTCAAATAGGGTTCATGCGAGCG  40 
 45 GAGCTGGGCTCAGGAGTTGGGAGCCCCGATCATCTCGATT  40 
 46 TTCCGGAGCCAAGGAGTAATCAATCGAGATGATCGGGGCT  40 
 47 ACTCCTTGGCTCCGGAAGCTCCATTCCCGCGTGCTTTGGA  40 
 48 CCAGCAATAAGCAAAGAAGCATTCCTCCAAAGCACGCGGG  40 
 49 AATGCTTCTTTGCTTATTGCTGGGCCATCAAGCACTGCGC  40 
 50 CGTTCACCCGTCGATCCCAACAGGGCGCAGTGCTTGATGG  40 
 51 GGATCGACGGGTGAACGCATTTGTTTGGCCGGATAGACCC  40 
 52 GGGGACCACTTTGTACAAGAAAGCTGGGTCTATCCGGCCAAAC  43 
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The following are the protein sequences and list of primers used for P3 gene synthesis. 
 
Protein sequence for synthesis:  
 
DSAGGNLCFTVALRAAAYGVRVPDGIMAAYPATMLQPAASPSRLLSLMDPLLPLSVLSKCVSAYAGAKTED
HSNSDQKALGMMGLVRRDTALLLRDFRLGASSWLNSFLELSGRKSQKMSEPIAEPMRRSVSEAALAQPQG
PLGTDSLKNLTLRDLSLRGNSETSSDTPEMSLSAETLSPSTPSDVNFLLPPEDAGEEAEAKNELSPMDRGLG
VRAAFPEGFHPRRSSQGATQMPLYSSPIVKNPFMSPLLAPDSMLKSLPPVHIVACALDPMLDDSVMLARRL
RNLGQPVTLRVVEDLPHGFLTLAALCRETRQAAELCVERIRLVLTPPAGAGPSGETGAAGVDGGCGGRH 
DNA sequence after addition of GATEWAY recombination sequences: 
Gateway 5’ end 
GGGGACAAGTTTGTACAAAAAAGCAGGCT 
Gateway 3’ end 
ACCCAGCTTTCTTGTACAAAGTGGTCCCC 
 
1 GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGATTCCGCCGGTGGTAACTTGTGCTTTA 
  61 CGGTCGCTTTGCGTGCTGCTGCTTACGGCGTCCGTGTCCCGGATGGCATTATGGCTGCCT 
 121 ATCCCGCCACGATGCTGCAACCAGCTGCCTCCCCATCCCGTTTGTTGAGCCTGATGGACC 
 181 CGCTGTTGCCCTTGTCCGTCTTGTCCAAGTGCGTCTCCGCTTACGCCGGAGCCAAGACCG 
 241 AAGACCACTCCAATTCCGACCAAAAAGCTCTGGGCATGATGGGATTGGTGCGTCGCGATA 
 301 CGGCTTTGTTGTTGCGCGACTTTCGTTTGGGCGCCTCCTCCTGGTTGAACAGCTTCCTGG 
 361 AGTTGAGCGGTCGTAAATCCCAGAAAATGTCCGAACCAATTGCCGAGCCCATGCGCCGCT 
 421 CGGTCAGCGAAGCTGCCCTGGCCCAACCACAAGGTCCCCTGGGTACCGACAGCCTGAAAA 
 481 ACTTGACCTTGCGTGATTTGTCGCTGCGCGGTAATTCGGAAACGTCCTCGGACACCCCGG 
 541 AGATGTCGTTGTCCGCCGAAACCCTGAGCCCCTCGACGCCATCGGACGTCAACTTTTTGT 
 601 TGCCACCGGAAGATGCTGGTGAAGAGGCTGAGGCTAAAAACGAACTGTCGCCGATGGATC 
 661 GCGGTCTGGGAGTGCGTGCCGCCTTTCCAGAAGGATTTCATCCACGTCGTAGCTCCCAAG 
 721 GAGCCACCCAGATGCCATTGTACAGCTCGCCAATTGTCAAAAATCCATTCATGTCCCCCC 
 781 TGCTGGCCCCAGACAGCATGTTGAAGTCCCTGCCACCAGTCCATATTGTGGCTTGCGCTC 
 841 TGGACCCCATGCTGGACGACTCGGTGATGTTGGCCCGTCGTCTGCGCAATTTGGGACAGC 
 901 CCGTCACGCTGCGTGTGGTCGAGGACTTGCCGCATGGCTTTCTGACGTTGGCTGCTTTGT 
 961 GTCGCGAAACGCGTCAGGCCGCTGAGTTGTGTGTGGAACGCATCCGCTTGGTCTTGACGC 
1021 CGCCAGCCGGTGCCGGACCGTCGGGTGAGACGGGAGCCGCTGGCGTGGACGGTGGTTGCG 
1081 GCGGTCGCCATTAGCTCGAGTCTAGAACCCAGCTTTCTTGTACAAAGTGGTCCCC 
 
Gene synthesis:  
 
  1 GGGGACAAGTTTGTACAAAAAAGCAGGCTAT  31 
  2 CCACCGGCGGAATCCATAGCCTGCTTTTTTGTACAAACTT  40 
  3 GGATTCCGCCGGTGGTAACTTGTGCTTTACGGTCGCTTTG  40 
  4 GACGCCGTAAGCAGCAGCACGCAAAGCGACCGTAAAGCAC  40 
  5 CTGCTGCTTACGGCGTCCGTGTCCCGGATGGCATTATGGC  40 
  6 CAGCATCGTGGCGGGATAGGCAGCCATAATGCCATCCGGG  40 
  7 CCCGCCACGATGCTGCAACCAGCTGCCTCCCCATCCCGTT  40 
  8 ACAGCGGGTCCATCAGGCTCAACAAACGGGATGGGGAGGC  40 
  9 CCTGATGGACCCGCTGTTGCCCTTGTCCGTCTTGTCCAAG  40 
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 10 CCGGCGTAAGCGGAGACGCACTTGGACAAGACGGACAAGG  40 
 11 CTCCGCTTACGCCGGAGCCAAGACCGAAGACCACTCCAAT  40 
 12 CCAGAGCTTTTTGGTCGGAATTGGAGTGGTCTTCGGTCTT  40 
 13 TCCGACCAAAAAGCTCTGGGCATGATGGGATTGGTGCGTC  40 
 14 GCAACAACAAAGCCGTATCGCGACGCACCAATCCCATCAT  40 
 15 CGATACGGCTTTGTTGTTGCGCGACTTTCGTTTGGGCGCC  40 
 16 AGGAAGCTGTTCAACCAGGAGGAGGCGCCCAAACGAAAGT  40 
 17 TCCTGGTTGAACAGCTTCCTGGAGTTGAGCGGTCGTAAAT  40 
 18 TGGTTCGGACATTTTCTGGGATTTACGACCGCTCAACTCC  40 
 19 CCCAGAAAATGTCCGAACCAATTGCCGAGCCCATGCGCCG  40 
 20 GGGCCAGGGCAGCTTCGCTGACCGAGCGGCGCATGGGCTC  40 
 21 AGCTGCCCTGGCCCAACCACAAGGTCCCCTGGGTACCGAC  40 
 22 CGCAAGGTCAAGTTTTTCAGGCTGTCGGTACCCAGGGGAC  40 
 23 CCTGAAAAACTTGACCTTGCGTGATTTGTCGCTGCGCGGT  40 
 24 CGGGGTGTCCGAGGACGTTTCCGAATTACCGCGCAGCGAC  40 
 25 TCCTCGGACACCCCGGAGATGTCGTTGTCCGCCGAAACCC  40 
 26 GTCCGATGGCGTCGAGGGGCTCAGGGTTTCGGCGGACAAC  40 
 27 CTCGACGCCATCGGACGTCAACTTTTTGTTGCCACCGGAA  40 
 28 CAGCCTCTTCACCAGCATCTTCCGGTGGCAACAAAAAGTT  40 
 29 GATGCTGGTGAAGAGGCTGAGGCTAAAAACGAACTGTCGC  40 
 30 CCCAGACCGCGATCCATCGGCGACAGTTCGTTTTTAGCCT  40 
 31 TGGATCGCGGTCTGGGAGTGCGTGCCGCCTTTCCAGAAGG  40 
 32 GGGAGCTACGACGTGGATGAAATCCTTCTGGAAAGGCGGC  40 
 33 TCCACGTCGTAGCTCCCAAGGAGCCACCCAGATGCCATTG  40 
 34 TTTTGACAATTGGCGAGCTGTACAATGGCATCTGGGTGGC  40 
 35 ACAGCTCGCCAATTGTCAAAAATCCATTCATGTCCCCCCT  40 
 36 AACATGCTGTCTGGGGCCAGCAGGGGGGACATGAATGGAT  40 
 37 GCCCCAGACAGCATGTTGAAGTCCCTGCCACCAGTCCATA  40 
 38 GGGTCCAGAGCGCAAGCCACAATATGGACTGGTGGCAGGG  40 
 39 CTTGCGCTCTGGACCCCATGCTGGACGACTCGGTGATGTT  40 
 40 AAATTGCGCAGACGACGGGCCAACATCACCGAGTCGTCCA  40 
 41 CCGTCGTCTGCGCAATTTGGGACAGCCCGTCACGCTGCGT  40 
 42 AAGCCATGCGGCAAGTCCTCGACCACACGCAGCGTGACGG  40 
 43 GACTTGCCGCATGGCTTTCTGACGTTGGCTGCTTTGTGTC  40 
 44 CAGCGGCCTGACGCGTTTCGCGACACAAAGCAGCCAACGT  40 
 45 GCGTCAGGCCGCTGAGTTGTGTGTGGAACGCATCCGCTTG  40 
 46 GCACCGGCTGGCGGCGTCAAGACCAAGCGGATGCGTTCCA  40 
 47 CGCCAGCCGGTGCCGGACCGTCGGGTGAGACGGGAGCCGC  40 
 48 ACCGCCGCAACCACCGTCCACGCCAGCGGCTCCCGTCTCA  40 
 49 GTGGTTGCGGCGGTCGCCATTAGCTCGAGTCTAGAACCCA  40 
 50 GGGGACCACTTTGTACAAGAAAGCTGGGTTCTAGACTCGAGCTAA  45 
 
 
 
 
